JNJ Stock Analysis

Is JNJ a good stock to buy right now?

Whether JNJ is a buy depends on its current technical positioning. JNJ is the anchor holding in virtually every large institutional healthcare portfolio — its Dividend King status and AAA credit rating (one of only two U.S. companies with this rating) make it a "must own" for income and quality investors. ATR of 1-1.5% is among the lowest of any S&P 500 stock. JNJ functions as a sector sentiment indicator: when JNJ is weak, the whole healthcare sector is under pressure. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals — updated every trading day.

What are the most important technical signals for JNJ?

The four key signals for JNJ are: RSI Behavior (Ultra-stable 42-65 range) — JNJ's extreme earnings stability produces the most predictable RSI behavior of any healthcare stock. RSI below 45 on JNJ is a reliable buy signal — income and quality investors immediately accumulate at those levels. The stock rarely stays below RSI 45 for more than 2-3 weeks before recovering.. Pharmaceutical Pipeline (Oncology growth driver) — JNJ's oncology segment — featuring multiple myeloma drug Darzalex and prostate cancer drug Erleada — is its fastest-growing pharmaceutical franchise. Phase 3 data readouts from oncology pipeline compounds have produced 3-5% moves. Monitor ASCO and ASH conference abstracts for pipeline catalysts 6-8 weeks before major oncology conferences.. Talc Litigation (Ongoing legal overhang) — JNJ's talc-related lawsuits (from its former consumer business, retained post-Kenvue spinoff) create persistent legal overhang. Adverse court rulings or failed bankruptcy settlement attempts have produced 3-7% single-day selloffs. Monitor Texas Two-Step bankruptcy proceeding updates as binary risk events.. Dividend Growth (61+ consecutive years) — JNJ's 61-year dividend growth streak creates automatic institutional demand at any point the dividend yield rises meaningfully above 3% — income-focused funds and ETFs that track dividend aristocrats generate systematic buying pressure that limits downside at these yield levels.

What is JNJ's RSI telling traders right now?

JNJ's extreme earnings stability produces the most predictable RSI behavior of any healthcare stock. RSI below 45 on JNJ is a reliable buy signal — income and quality investors immediately accumulate at those levels. The stock rarely stays below RSI 45 for more than 2-3 weeks before recovering. APEX scores JNJ's RSI as part of its 8-factor composite signal — updated daily.

How does JNJ behave technically compared to other Healthcare / Pharmaceutical / MedTech stocks?

JNJ is in the Healthcare / Pharmaceutical / MedTech sector. Johnson & Johnson is a diversified healthcare company with two primary segments: Innovative Medicine (pharmaceuticals including immunology blockbusters Stelara and Tremfya, plus oncology) and MedTech (surgical robotics, orthopedics, cardiovascular). JNJ completed the spinoff of its consumer products division (Kenvue) in 2023, transforming itself into a pure-play healthcare company with higher growth and margins. JNJ has raised its dividend for 61 consecutive years — one of the longest streaks in any industry. Key stats: ATR (14-day): 1-1.5% of price, Avg daily volume: ~7-12 million shares, Key metric: Darzalex growth + MedTech revenue, Dividend streak: 61+ consecutive years.

What MACD signals work best for JNJ?

MACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks JNJ's MACD histogram direction daily.